Clinical Identification and Management of Hypertension in a Primary Care Setting at Segala Mider Public Health Center

Authors

  • Nita Sahara Faculty of Medicine, Malahayati University Bandar Lampung, Indonesia Author
  • Destriana Hasan Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author
  • A Fatwa Alwaliu Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author
  • Achmad Farhan Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author
  • Adelia Putri Sardi Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author
  • Adis Adelia Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author
  • Ady Wahyu Pratama Medical Study Program, Malahayati University Bandar Lampung, Indonesia Author

DOI:

https://doi.org/10.58524/brtl.v1i2.79

Keywords:

hypertension, primary care, blood pressure management, clinical identification, cardiovascular risk

Abstract

Hypertension remains a major global health challenge and a leading contributor to cardiovascular morbidity and mortality. Its asymptomatic nature causes many individuals to remain undiagnosed, increasing the risk of severe complications such as stroke, coronary artery disease, and renal impairment. Despite advancements in diagnostic and therapeutic approaches, hypertension awareness and treatment adherence remain low, particularly in primary care settings where early detection is crucial. This study describes the clinical identification and management process of a hypertensive adult patient at Segala Mider Public Health Center as an illustration of the essential role of primary healthcare services in improving hypertension control at the community level. Clinical data were collected through patient interviews, vital sign assessment, physical examination, and review of medical records. The patient, a 42-year-old male, presented with recurrent dizziness triggered by physical activity and consumption of sweet foods. Initial evaluation showed severely elevated blood pressure at 164/122 mmHg with otherwise normal cardiopulmonary findings. The patient had previously been taking amlodipine 5 mg daily with suboptimal response. Management involved titration of amlodipine to 10 mg daily for 15 days, accompanied by short-term furosemide therapy and vitamin B complex supplementation. The intervention produced symptomatic improvement and facilitated better blood pressure control during follow-up. The findings highlight the importance of timely recognition of uncontrolled hypertension, appropriate pharmacological adjustment, and continuous monitoring. This report emphasizes the relevance of primary care in initiating evidence-based treatment, identifying modifiable risk factors, and ensuring patient education regarding lifestyle modification. The novelty of this study lies in demonstrating how structured evaluation and treatment optimization in a resource-limited primary care setting can effectively support hypertension control while preventing long-term complications, reinforcing the vital role of frontline healthcare facilities in managing chronic diseases.

References

ALLHAT Collaborative Research Group. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 288(23), 2981–2997.

Ayuning Siwi, P. (2024). Primary care screening strategies for early detection of hypertension in adults. Journal of Primary Health Services, 12(1), 45–52.

Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., … & Douglas, J. (2020). Clinical outcomes with amlodipine-based therapy in hypertension. Journal of Clinical Hypertension, 22(5), 774–783.

Beaney, T., Schutte, A. E., Tomaszewski, M., et al. (2020). May Measurement Month: Global screening for hypertension. The Lancet Global Health, 8(1), e54–e66.

Burnier, M., & Egan, B. M. (2019). Adherence in hypertension management. Circulation Research, 124(7), 1124–1140.

Carretero, O. A., & Oparil, S. (2000). Essential hypertension. Circulation, 101(3), 329–335.

Chrysant, S. G. (2017). Antihypertensive effectiveness of amlodipine. American Journal of Cardiology, 120(suppl), S32–S41.

Ettehad, D., Emdin, C. A., Kiran, A., et al. (2016). Blood pressure lowering for prevention of cardiovascular events. The Lancet, 387(10022), 957–967.

Forouzanfar, M. H., Liu, P., Roth, G. A., et al. (2017). Global burden of hypertension. JAMA, 317(2), 165–182.

Grassi, G., Seravalle, G., & Mancia, G. (2019). Sympathetic activation in hypertension. Journal of Hypertension, 37(8), 1557–1565.

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2021). Obesity-induced hypertension. Hypertension, 75(2), 1–12.

He, F. J., Tan, M., Ma, Y., & MacGregor, G. A. (2020). Sugar consumption and blood pressure. Hypertension, 76(2), 394–400.

Houston, M. (2018). Micronutrient deficiencies in hypertension. Cardiology Clinics, 36(2), 237–254.

Kandarini, Y. (2013). Hypertension management and guideline adherence in Indonesian health facilities. Indonesian Journal of Clinical Medicine, 2(3), 120–128.

Kementerian Kesehatan Republik Indonesia. (2023). Survei Kesehatan Indonesia 2023. Kemenkes RI.

Lamangida, A., Yusuf, R., & Prasetyo, A. (2025). Lifestyle determinants of hypertension among Indonesian adults: A community-based analysis. Journal of Preventive Cardiology, 18(2), 88–96.

Lu, J., Lu, Y., Wang, X., Li, X., & Linderman, G. (2022). Uncontrolled hypertension worldwide: A systematic analysis of treatment gaps. The Lancet, 400(10357), 957–968.

Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223–237.

Mozaffarian, D. (2016). Dietary influences on hypertension. Circulation Research, 118(3), 620–640.

Padwal, R., Campbell, N. R. C., & Schutte, A. E. (2019). Lifestyle modification in hypertension. Nature Reviews Cardiology, 16(1), 1–14.

Peixoto, A. J. (2019). Acute severe hypertension. New England Journal of Medicine, 381(19), 1843–1852.

Rodriguez, M. A., Kumar, S. K., & De Caro, M. (2017). Hypertensive crisis. Cardiology in Review, 18(2), 102–107.

Sica, D. A. (2011). Diuretics and blood pressure management. Journal of Clinical Hypertension, 13(9), 639–643.

SPRINT Research Group. (2015). A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine, 373(22), 2103–2116.

Sudirman, S., & Monoarfa, F. (2022). Silent progression of hypertension and its clinical implications. Southeast Asian Journal of Internal Medicine, 11(3), 210–217.

Ungar, A., Rivasi, G., Petrovic, M., et al. (2021). Hypertension care in primary settings. European Journal of Internal Medicine, 89, 1–9.

Unger, T., Borghi, C., Charchar, F., et al. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334–1357.

Wahidin, U., Rachmawati, T., & Suhadi, R. (2025). Hypertension risk patterns among Indonesian adults: A nationwide analysis. International Journal of Public Health Research, 9(1), 34–42.

Whelton, P. K., & Williams, B. (2018). Hypertension pathophysiology. Lancet, 392(10161), 801–813.

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127–e248.

World Health Organization. (2021). Global health estimates 2021: Deaths by cause, age, sex, by country and region, 2000–2021. WHO.

Yusuf, S., Sleight, P., Pogue, J., et al. (2000). Effects of ACE inhibitor ramipril. New England Journal of Medicine, 342(3), 145–153.

Zhou, B., Carrillo-Larco, R. M., Danaei, G., et al. (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. The Lancet, 398(10304), 957–980.

Downloads

Published

2025-10-30